Adherence to Tobramycin Inhalation Solution in Cystic Fibrosis Patients
Author Information
Author(s): Briesacher Becky A, Quittner Alexandra L, Saiman Lisa, Sacco Patricia, Fouayzi Hassan, Quittell Lynne M
Primary Institution: University of Massachusetts Medical School
Hypothesis
Does adherence to tobramycin inhalation solution (TIS) during routine cystic fibrosis care affect health care utilization?
Conclusion
High utilization of TIS was infrequent but associated with a decreased risk of hospitalization.
Supporting Evidence
- Only 7% of individuals received 4 or more cycles of TIS per year.
- High adherence was linked to a 60% reduction in hospitalization risk.
- Median outpatient costs were lower for high TIS users compared to low users.
Takeaway
This study found that many cystic fibrosis patients are not using their prescribed inhaled medication as often as they should, which can lead to more hospital visits.
Methodology
Analyzed healthcare claims data from 2001-2006 for individuals with cystic fibrosis who had prescriptions for TIS.
Potential Biases
Potential under-coding of P. aeruginosa infections and failure to thrive due to lack of financial incentive.
Limitations
The study relied on pharmacy claims records, which may not accurately reflect actual medication exposure, and the sample may not be generalizable to all cystic fibrosis patients.
Participant Demographics
{"age_distribution":{"<6":"13.2%","6-10":"12.2%","11-17":"31.5%","18-25":"22.0%","≥26":"21.1%"},"gender_distribution":{"male":"52.7%","female":"47.3%"},"comorbidity":{"higher_than_average":"34.7%","average_or_lower":"65.3%"},"geographic_region":{"Northeast":"12.3%","Midwest":"27.0%","South":"39.1%","West":"21.4%"}}
Statistical Information
P-Value
0.40
Confidence Interval
0.19-0.84
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website